Anti-C1q Antibody Composition for Complement-Mediated Retinal Damage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inherited retinal diseases (IRDs) and retinal detachment are limited, with no gene-agnostic therapies and insufficient visual recovery post-surgery, highlighting a significant unmet need for effective interventions.
Innovation Solution
Administration of an anti-C1q antibody, specifically a recombinant humanized IgG1 antigen-binding fragment (Fab) via intravitreal injection, which inhibits the classical complement cascade to reduce neuronal and synaptic damage, thereby treating IRDs and retinal detachment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene-specific therapies (e.g., voretigene neparvovec for RPE65) are used to treat inherited retinal diseases, then treatment effectiveness is improved for specific genetic mutations, but applicability is limited to only 1-2% of IRD patients
Solution Approach 1:
The patent employs a gene-agnostic therapeutic approach using anti-C1q antibody that targets the complement pathway rather than specific genetic mutations. This universal mechanism can be applied across multiple IRD types and genetic defects, making the treatment versatile while maintaining effectiveness through a common pathological target (complement-mediated photoreceptor damage)
2Ease of operation
If retinal prosthetic devices are used to convert light to electrical energy, then visual stimulation is achieved, but the underlying pathophysiology of the disease is not addressed
Solution Approach 1:
The patent targets the harmful complement activation pathway that causes photoreceptor damage and converts it into a therapeutic opportunity. By administering anti-C1q antibody, the harmful complement-mediated inflammation is blocked, thereby protecting photoreceptors and potentially restoring endogenous visual function rather than relying on external prosthetic stimulation
3Stability of the object's composition
If macula-off retinal detachment surgery is performed to re-attach the retina, then anatomical recovery is achieved, but visual acuity recovery is limited to about 50% of pre-detachment levels due to photoreceptor degeneration
Solution Approach 1:
The patent administers anti-C1q antibody before retinal detachment surgery to prevent complement activation and photoreceptor damage during the surgical procedure and recovery period. This preliminary protective action preserves photoreceptor function, enabling better visual acuity recovery beyond the typical 50% limitation while maintaining the anatomical re-attachment achieved by surgery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-C1q antibody effectively reduces inflammation and preserves photoreceptor synapses, improving vision and retinal function in patients with IRDs and post-retinal detachment surgery.
Implementation Method 1
administering to the patient a composition comprising about 1 mg to about 10 mg of an anti-C1q antibody... which inhibits the classical complement cascade
Data Source
AI summary
The present disclosure relates generally to compositions and methods of preventing, reducing risk of developing, or treating an inherited retinal disease (IRD) (e.g., retinitis pigmentosa, choroideremia, Stargardt disease, cone-rod dystrophy, leber congenital amaurosis), X-linked RP, and Usher Syndrome or retinal detachment.